Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.44 |
| ▸ | CA12 | O43570 | 2/20 | 0.44 |
| ▸ | CA1 | P00915 | 2/20 | 0.44 |
| ▸ | CA2 | P00918 | 2/20 | 0.44 |
| ▸ | CA7 | P43166 | 2/20 | 0.44 |
| ▸ | CA9 | Q16790 | 2/20 | 0.44 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | CA3 | P07451 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | SELL | P14151 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | SELP | P16109 | 1/20 | 0.44 |
| ▸ | FUT4 | P22083 | 1/20 | 0.44 |
| ▸ | CA4 | P22748 | 1/20 | 0.44 |
| ▸ | CA6 | P23280 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24426994 | 0.86 | KDM4E (0.39) | LMNAALDH1A1MAPK1CA12CA1 | |
| SCHEMBL15321929 | 0.86 | MAPT (0.42) | LMNAALDH1A1MAPK1CA12CA1 | |
| SCHEMBL15323116 | 0.86 | TTR (0.48) | LMNAALDH1A1MAPK1CA12CA1 | |
| SCHEMBL20196046 | 0.86 | TTR (0.48) | LMNAALDH1A1MAPK1CA12CA1 | |
| SCHEMBL22168037 | 0.80 | CA5A (0.43) | LMNAALDH1A1CA5AERN1CES2 | |
| SCHEMBL28972927 | 0.78 | CES2 (0.33) | LMNAMAPK1MAPTERN1HTT | |
| SCHEMBL25567670 | 0.77 | HDAC6 (0.60) | CA12CA1CA9KDM4EHSD17B10 | |
| SCHEMBL221480 | 0.75 | CES2 (0.67) | LMNAALDH1A1MAPK1CA12CA1 | |
| SCHEMBL14213195 | 0.75 | TTR (0.55) | LMNAALDH1A1MAPK1CA12CA1 | |
| SCHEMBL22465969 | 0.75 | ERN1 (0.66) | LMNAALDH1A1MAPK1CA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 82 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112409331-B | Heterocyclic derivative inhibitor, preparation method and application thereof | 上海翰森生物医药科技有限公司 | 2024-02-20 | — | — | CN | disclosed |
| US-20240034729-A9 | HETEROCYCLIC COMPOUND, INTERMEDIATE, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | WUHAN LL SCIENCE AND TECHNOLOGY DEVELOPMENT CO., LTD. (CN) | 2024-02-01 | — | — | US | disclosed |
| US-20230406851-A1 | IMIDAZOPYRIDINE COMPOUNDS AND USES THEREOF | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.3) LIMITED (GB) | 2023-12-21 | — | — | US | disclosed |
| US-20230348779-A1 | FLUORESCENT COMPOUND AND FLUORESCENTLY LABELED BIOLOGICAL SUBSTANCE USING THE SAME | FUJIFILM CORPORATION (JP) | 2023-11-02 | — | — | US | disclosed |
| US-20230348779-A1 | FLUORESCENT COMPOUND AND FLUORESCENTLY LABELED BIOLOGICAL SUBSTANCE USING THE SAME | FUJIFILM CORPORATION (JP) | 2023-11-02 | — | — | US | disclosed |
| US-20230348779-A1 | FLUORESCENT COMPOUND AND FLUORESCENTLY LABELED BIOLOGICAL SUBSTANCE USING THE SAME | FUJIFILM CORPORATION (JP) | 2023-11-02 | — | — | US | disclosed |
| CN-116635389-A | Morpholine derivative, pharmaceutical composition and application thereof | 上海海雁医药科技有限公司 | 2023-08-22 | — | — | CN | disclosed |
| CN-114085220-B | Substituted morpholine-4-carboxylic acid ester derivatives, compositions and pharmaceutical uses thereof | 上海海雁医药科技有限公司 | 2023-06-16 | — | — | CN | disclosed |
| WO-2023097386-A1 | SELECTIVE HDAC6-INHIBITING N-ACYLHYDRAZONE COMPOUNDS, METHODS FOR PRODUCING SAME, COMPOSITIONS, USES, TREATMENT METHODS AND KITS | EUROFARMA LABORATÓRIOS S.A (BR) | 2023-06-08 | — | — | WO | disclosed |
| US-20230068538-A1 | HETEROCYCLIC COMPOUND, INTERMEDIATE, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | WUHAN LL SCIENCE & TECHNOLOGY DEVELOPMENT CO LTD (CN) | 2023-03-02 | — | — | US | disclosed |
| WO-2012160464-A1 | HETEROCYCLIC COMPOUNDS AS PROTEIN KINASE INHIBITORS | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-11-29 | — | — | WO | disclosed |
| WO-2012158117-A1 | COMBINATION THERAPIES FOR TREATING PAIN | ASTRAZENECA AB (SE) | 2012-11-22 | — | — | WO | disclosed |
| US-20120289504-A1 | Benzoimidazole Compounds and Uses Thereof | ASTRAZENECA AB (SE) | 2012-11-15 | — | — | US | disclosed |
| US-20120289504-A1 | Benzoimidazole Compounds and Uses Thereof | ASTRAZENECA AB (SE) | 2012-11-15 | — | — | US | disclosed |
| US-20120289504-A1 | Benzoimidazole Compounds and Uses Thereof | ASTRAZENECA AB (SE) | 2012-11-15 | — | — | US | disclosed |
| EP-2501697-A1 | BENZOIMIDAZOLE COMPOUNDS AND USES THEREOF | AstraZeneca AB (SE) | 2012-09-26 | — | — | EP | disclosed |
| WO-2011062550-A1 | BENZOIMIDAZOLE COMPOUNDS AND USES THEREOF | ASTRAZENECA AB (SE) | 2011-05-26 | — | — | WO | disclosed |
| EP-1572693-A1 | MITOGEN ACTIVATED PROTEIN KINASE-ACTIVATED PROTEIN KINASE-2 INHIBITING COMPOUNDS | Pharmacia Corporation (US) | 2005-09-14 | — | — | EP | disclosed |
| US-20040209897-A1 | Mitogen activated protein kinase-activated protein kinase-2 inhibiting compounds | PHARMACIA CORPORATION | 2004-10-21 | — | — | US | disclosed |
| WO-2004058762-A1 | MITOGEN ACTIVATED PROTEIN KINASE-ACTIVATED PROTEIN KINASE-2 INHIBITING COMPOUNDS | PHARMACIA CORPORATION (US) | 2004-07-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230406851-A1 | IMIDAZOPYRIDINE COMPOUNDS AND USES THEREOF | NISCH, ABL1, PAICS | LMNA 1763/4885ALDH1A1 664/4885MAPK1 2046/4885 |
| US-20230068538-A1 | HETEROCYCLIC COMPOUND, INTERMEDIATE, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | P2RX3, P2RX7, P2RX4 | LMNA 2553/4885ALDH1A1 996/4885MAPK1 2874/4885 |
| US-20040209897-A1 | Mitogen activated protein kinase-activated protein kinase-2 inhibiting compounds | MAPKAPK2, MAP3K2, MKNK2 | LMNA 3207/4885ALDH1A1 4638/4885MAPK1 30/4885 |
| US-20120289504-A1 | Benzoimidazole Compounds and Uses Thereof | TPMT, BRD4, CYP3A4 | LMNA 2661/4885ALDH1A1 441/4885MAPK1 3211/4885 |
| US-20240034729-A9 | HETEROCYCLIC COMPOUND, INTERMEDIATE, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | P2RX3, P2RX7, P2RX4 | LMNA 2553/4885ALDH1A1 996/4885MAPK1 2874/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.